In brief
- Eli Lilly announces the acquisition of AtaiBeckley for up to $3.8 billion, according to a 16 July corporate release, without current closing verified here
- The lead asset is BPL-003, a synthetic 5-MeO-DMT nasal spray for which the release describes initiation of phase 3 activities in treatment-resistant depression
- The pipeline also includes VLS-01, a DMT buccal film, and EMP-01, an MDMA-derived candidate for social anxiety
One of the world’s largest pharmaceutical companies just put a price tag on a synthetic formulation of 5-MeO-DMT. On July 16, Eli Lilly announced a definitive agreement to acquire AtaiBeckley, the biopharmaceutical company developing therapies based on 5-MeO-DMT and DMT for mental health conditions. The announcement reflects corporate interest but does not establish current completion or a historical ranking of all sector transactions.
A figure you don’t see every day
According to the joint press release from both companies, Lilly will pay $6.75 per share in cash, roughly $2.8 billion in total, representing a premium of nearly 40% over AtaiBeckley’s average trading price during the prior 30 days. On top of that, there is a contingent value right (CVR) of up to $2.50 per share, approximately $1 billion more, with no guaranteed payout and milestones required within four, five and seven years after closing, respectively: $1.00 when VLS-01 enters phase 3, $0.50 when BPL-003 secures FDA approval and DEA rescheduling, and another $1.00 when VLS-01 achieves both. In total, the deal could reach $3.8 billion. Lilly did not attach any financing conditions to the agreement, whose closing the July release forecast for the third quarter of 2026, subject to shareholder approval, regulatory approvals and other conditions. This review does not confirm completion.
What exactly is BPL-003
The asset of greatest interest to Lilly is BPL-003, scientifically known as mebufotenin benzoate: a synthetic formulation of 5-MeO-DMT administered intranasally during a single clinical visit lasting around two hours. The release describes FDA Breakthrough Therapy designation and favorable phase 2b findings according to the company; this review did not read the full clinical report. It also says phase 3 activities had begun, which does not confirm enrollment, outcomes or approval. AtaiBeckley’s pipeline does not end there: it also includes VLS-01, a DMT buccal film targeting treatment-resistant depression in phase 2b, and EMP-01, a form of MDMA designed for social anxiety disorder, currently in phase 2.
What this means
An announced financial commitment is not completed spending, proven clinical efficacy or marketing authorization. The acquisition will not change the legal status of 5-MeO-DMT or DMT overnight: part of the payout depends precisely on the DEA rescheduling these compounds if the FDA ultimately approves them as medicines. This is a business transaction, not a completed regulatory overhaul, and it should be interpreted with appropriate caution. Yet for those who have spent years documenting the therapeutic potential of these molecules, seeing conventional pharma wager billions on them is a signal hard to overlook, even if the road to an approved, accessible drug remains long.
Source
- Eli Lilly and Company / AtaiBeckley Inc. Lilly to Acquire AtaiBeckley to Advance Therapies for Treatment-Resistant Depression and Other Mental Health Conditions. PR Newswire, July 16, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
